A Case of Type I Sialidosis with Osteonecrosis Revealing a New

A Case of Type I Sialidosis with Osteonecrosis Revealing a New

Original Article Journal of Inborn Errors of Metabolism &Screening 1–3 A Case of Type I Sialidosis With ª The Author(s) 2014 Reprints and permission: Osteonecrosis Revealing a New sagepub.com/journalsPermissions.nav DOI: 10.1177/2326409814543468 Mutation in NEU1 iem.sagepub.com Geoffrey Urbanski1,2, Soumeya Bekri3, Magalie Barth2,4, Christophe Verny4, and Christian Lavigne1,2 Abstract Sialidosis is a rare lysosomal storage disease. The 2 forms described are as follows: the early-onset form, or type II, presents with dysostosis multiplex, while the late-onset form, or type I, does not involve bone in the literature. We report the case of a 42-year- old woman with type I sialidosis who presents with osteonecrosis of both humeral and femoral heads. Molecular study reveals a never listed mutation of NEU1 in exon 5, p.Gly273Asp (c.818G>A), and a second known missense mutation. Keywords sialidosis, bone involvement, NEU1 Introduction developed, at the age of 18 years, a rapidly progressive severe bilateral visual defect leading to blindness. At that time, the Sialidosis (Online Mendelian Inheritance in Man [OMIM] ophthalmologic examination revealed bilateral cherry red spot 256550) is a rare lysosomal storage disease,1 with an estimated in the macula, evolving to macular and optic atrophy associated incidence of 1 in 4 200 000 live births, and it belongs to the group with bilateral cataract. At the age of 32 years, she developed of oligosaccharidoses. Sialidosis is caused by to the recessively myoclonus and epilepsy as grand mal seizure. Myoclonus inherited deficiency of N-acetyl-a-neuraminidase, an acid affected all 4 limbs, but prevailed in the upper limbs, and hydrolase expressed from the gene NEU1, which is located in increased with menstrual cycle and anxiety. Neurologic exam- 6p21 and cleaves terminal alpha 2 > 3 and alpha 2 > 6 sialyl lin- ination showed diffuse hyperreflexia with left Hoffmann sign kages of oligosaccharides. This deficiency results in an accumu- and cerebellar ataxia. No mental retardation was found. Mag- lation of sialyloligosaccharides in tissues. Two groups of the netic resonance imaging (MRI) showed corticosubcortical atro- disease are distinguished. Type II sialidosis has an early onset phy prevailing in frontal lobes. Electroencephalography and is more severe with dysmorphic aspects, such as coarse showed salvo of slow waves in the frontal lobes. The patient facies and dysostosis multiplex, statural and mental retardation, was successively treated with valproate, lamotrigine, levetira- visceromegaly, myoclonus, seizure, and cherry red spots in the cetam associated with clobazam, and piracetam. Treatments macula. This type is divided into congenital, neonatal, and infan- were effective on for the seizures but were less effective for the tile forms. Type I sialidosis has a later onset and is more progres- myoclonus. sive. Type I, often diagnosed during the third or fourth decade, is less severe without physical changes (normosomatic) nor dysos- tosis multiplex and is essentially characterized by ocular and cer- 1 Internal Medicine Department, CHU Angers, Angers, France ebral involvement. We report the case of a patient with type I 2 Grand Ouest Metabolic Disorders Competence Center, CHU Angers, sialidosis who presents with unusual multiple osteonecrosis and Angers, France a nonpreviously reported mutation of NEU1. 3 Clinical Genetic Unit, CHU Rouen, Rouen, France 4 Neurogenetic Disease Reference Center, CHU Angers, Angers, France Case Report Corresponding Author: Geoffrey Urbanski, Internal Medicine Department, CHU Angers, 4 Rue Larrey A 42-year-old woman with a history of myoclonus, seizure, and 49933 Angers, France. blindness presented with pain in the left hip and left leg. She Email: [email protected] This article is distributed under the terms of the Creative Commons Attribution 3.0 License (http://www.creativecommons.org/licenses/by/3.0/) which permits any use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (http://www.uk.sagepub.com/aboutus/openaccess.htm). 2 Journal of Inborn Errors of Metabolism & Screening Metabolic assessment of urine samples found an accumula- multiple osteonecrosis could be related to sialadosis in this tion of complex sugars rich in sialic acid, with 4% and 14% patient. Sialidosis can involve bones in the early-onset form, strips on the thin-layer chromatography (Humbel technics), that is, type II, with dysostosis multiplex phenotype, but bone which evoked a neuraminidase deficiency. The diagnosis was abnormalities have never been described in type I. Neverthe- confirmed with evidence of absence of neuraminidase activity less, this disease is extremely rare and the initial description on fibroblast cultures (Supplementary Table 1). Beta- could be partial. galactosidase activity was normal, excluding galactosialidosis. Two missense mutations were identified in NEU1 gene, Hexosaminidase activity was also normal. p.Gly136Glu (c.407G>A) and p.Gly273Asp (c.818G>A). This Molecular study of NEU1 gene (NM_000434.2) helped in last mutation is novel. It is worth noting that not all missense the identification of 2 missense mutations. The first mutation mutations are deleterious. Because of the ambiguity of mis- was found in exon 3, p.Gly136Glu (c.407G>A), and was sense mutations, accurate tools that predict the effect of a given already reported.2 The second mutation was found in exon 5, point mutation on protein function are mandatory, and the use p.Gly273Asp (c.818G>A), and resulted in the substitution of of more than 1 algorithm is recommended.8 The 3 algorithms the acidic residue aspartic acid for the neutral wild-type residue used (SIFT,9 MutationTaster,10 and Polyphen-211) enabled us glycine at codon 273. This dramatic change in charge is consis- to conclude that this novel variant alters the protein function. tent with the presence of biochemical and clinical phenotypes. Another hint associated with the pathogenic effect of this muta- In addition, the concerned amino acid residue and nucleotide tion is its low frequency or absence in the general population. are highly conserved through evolution. This mutation has not We checked for the presence of the identified variant in the been reported yet. Exome Variant Server12; these mutations were not found At the age of 41 years, the patient felt pain in the left hip and among at least 8400 analyzed alleles. leg and developed progressive walking difficulties. The x-rays We report here the case of a 42-year-old patient with type I revealed an advanced-stage bilateral osteonecrosis of the hum- sialidosis who presents with severe bone involvement, such as eral (Supplementary Figure 1) and femoral heads (Supplemen- multiple osteonecrosis, and in whom the DNA sequencing tary Figure 2). Bone scintigraphy showed hyperfixation of both reveals an unknown mutation in the fifth exon of NEU1, femoral and humeral heads. Femoral x-rays also showed lytic c.818G>A. lesions on the diaphysis. The MRI confirmed osteonecrosis of both femoral and humeral heads and femoral diaphysis Declaration of Conflicting Interests infarcts. An exhaustive research excluded the usual causes of The author(s) declared no potential conflicts of interest with respect to osteonecrosis. Osteomedullary biopsy showed an important the research, authorship and/or publication of this article. infiltration of foamy macrophages and histiocytes as described in storage diseases. Bone biopsy did not reveal Gaucher cells. Funding Activities of tartrate-resistant acid phosphatases, chitotriosi- The author(s) received no financial support for the research and/or dase, and glucocerebrosidase were normal (Supplementary authorship of this article. Table 1), excluding Gaucher disease. Supplemental Material The online [supplements] are available at http://iem.sagepub.com/ Discussion supplemental. Avascular osteonecrosis is well described in the lysosomal stor- age diseases spectrum, such as Gaucher disease, and rarely References described in Fabry and Niemann-Pick type B diseases. Here, 1. Thomas GH. Disorders of glycoproteins degradation: a-mannosi- we excluded Gaucher disease with the normality of several bio- dosis, b-mannosidosis, fucosidosis, and sialidosis. In: Scriver C, logical parameters. The clinical presentation of this patient was ed. The Metabolic and Molecular Bases of Inherited Disease. not compatible with Fabry and Niemann-Pick type B diseases. 8th ed. McGraw-Hill Medical; 2001:3507-3533. Fabry disease is related to X-linked alpha-galactosidase A defi- 2. Seyrantepe V, Poupetova H, Froissart R, Zabot MT, Maire I, ciency and presents with acral paresthesias; angiokeratomas; and Pshezhetsky AV. Molecular pathology of NEU1 gene in sialido- renal, cerebral, and cardiac involvement. Niemann-Pick type B sis. Hum Mutat. 2003;22(5):343-352. disease presents with hepatomegaly, splenomegaly, and intersti- 3. Field RE, Buchanan JA, Copplemans MG, Aichroth PM. Bone- tial lung involvement without any neurologic symptoms. Apart marrow transplantation in Hurler’s syndrome. Effect on skeletal from sphingolipidosis, other lysosomal storage diseases of the development. J Bone Joint Surg Br. 1994;76(6):975-981. mucopolysaccharidosis group are associated with dysostosis 4. Ichikawa T, Nishimura G, Tsukune Y, Dezawa A, Miki H. multiplex, although rare cases of bone necrosis have been Progressive bone resorption after pathological fracture of the described in I, II, III, and

View Full Text

Details

  • File Type
    pdf
  • Upload Time
    -
  • Content Languages
    English
  • Upload User
    Anonymous/Not logged-in
  • File Pages
    3 Page
  • File Size
    -

Download

Channel Download Status
Express Download Enable

Copyright

We respect the copyrights and intellectual property rights of all users. All uploaded documents are either original works of the uploader or authorized works of the rightful owners.

  • Not to be reproduced or distributed without explicit permission.
  • Not used for commercial purposes outside of approved use cases.
  • Not used to infringe on the rights of the original creators.
  • If you believe any content infringes your copyright, please contact us immediately.

Support

For help with questions, suggestions, or problems, please contact us